Limits...
Evaluation of hydrophobic nanoparticulate delivery system for insulin.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Bottom Line: Insulin encapsulation efficiency was 95.7±1.2%.Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Insulin loaded hydrophobic nanoparticles were prepared by solvent diffusion followed by lyophilization. Nanoparticles were characterized for mean size by dynamic laser scattering and for shape by scanning electron microscopy. Insulin encapsulation efficiency, in vitro stability of nanoparticles in presence of proteolytic enzymes and in vitro release were determined by high pressure liquid chromatography analysis. The biological activity insulin from the nanopraticles was estimated by enzyme-linked immunosorbant assay and in vivo using Wister diabetic rats. Nanoparticles ranged 0.526±0.071 μm in diameter. Insulin encapsulation efficiency was 95.7±1.2%. Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.


Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3040864&req=5

Figure 0004: Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group

Mentions: Human insulin nanopartic1es (Group-3) significantly reduced the blood glucose levels over 4 to 12 h period compared to the placebo control (Group-1). Fig. 4 shows the blood glucose profile for each group. Hypoglycemic effect of the 20 IU/kg dose was almost similar to that with 2 IU/kg subcutaneous dose with respect to the extent of reduction in glucose concentration from base line (∼ 56% for 20 IU/kg-intragastrically administered human insulin nanoparic1es and ∼78.6% of baseline for 2 IU/kg subcutaneously injected human Insulin solution). Area above glucose concentration curves, AAC0-12h calculated from these curves as depicted in fig. 5 show that the effect of 20 IU/kg dose of nanopartic1e formulation was almost similar to subcutaneous injection of 2 IU/kg insulin while the effect of the latter was diminished at 6 h after injection, the former seemed to be continuing its hypoglycemic activity.


Evaluation of hydrophobic nanoparticulate delivery system for insulin.

Singnurkar PS, Gidwani SK - Indian J Pharm Sci (2008)

Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3040864&req=5

Figure 0004: Mean plasma Glucose concentration (%) versus time curve Plasma glucose levels in percentage after oral administration of 20 IU/kg Insulin nanoparticles (▪), Placebo nanoparticles equivalent to 20 IU/kg of insulin (▲), subcutaneous injection of 2 IU/kg human insulin solution (♦), n=6 per group
Mentions: Human insulin nanopartic1es (Group-3) significantly reduced the blood glucose levels over 4 to 12 h period compared to the placebo control (Group-1). Fig. 4 shows the blood glucose profile for each group. Hypoglycemic effect of the 20 IU/kg dose was almost similar to that with 2 IU/kg subcutaneous dose with respect to the extent of reduction in glucose concentration from base line (∼ 56% for 20 IU/kg-intragastrically administered human insulin nanoparic1es and ∼78.6% of baseline for 2 IU/kg subcutaneously injected human Insulin solution). Area above glucose concentration curves, AAC0-12h calculated from these curves as depicted in fig. 5 show that the effect of 20 IU/kg dose of nanopartic1e formulation was almost similar to subcutaneous injection of 2 IU/kg insulin while the effect of the latter was diminished at 6 h after injection, the former seemed to be continuing its hypoglycemic activity.

Bottom Line: Insulin encapsulation efficiency was 95.7±1.2%.Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin.Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

View Article: PubMed Central - PubMed

Affiliation: USV Limited, B. S. D. Marg, Govandi, Mumbai-400 088, India.

ABSTRACT
Insulin loaded hydrophobic nanoparticles were prepared by solvent diffusion followed by lyophilization. Nanoparticles were characterized for mean size by dynamic laser scattering and for shape by scanning electron microscopy. Insulin encapsulation efficiency, in vitro stability of nanoparticles in presence of proteolytic enzymes and in vitro release were determined by high pressure liquid chromatography analysis. The biological activity insulin from the nanopraticles was estimated by enzyme-linked immunosorbant assay and in vivo using Wister diabetic rats. Nanoparticles ranged 0.526±0.071 μm in diameter. Insulin encapsulation efficiency was 95.7±1.2%. Insulin hydrophobic nanoparticles suppressed insulin release promoted sustained release in pH 7.4 phosphate buffer and shown to protect insulin from enzymatic degradation in vitro in presence of chymotripsin. Nanoencapsulated insulin was bioactive, demonstrated through both in vivo and in vitro.

No MeSH data available.